Targeting the incretin system in obesity and type 2 diabetes mellitus

This article reviews advances in incretin-based pharmacotherapy, including the latest glucagon-like peptide 1 (GLP1) receptor agonists (GLP1RAs), ‘GLP1 plus’ agents, which combine the benefits of these agonists with the activity of additional hormones, and oral GLP1RAs, which promise to extend the benefits of GLP1 therapy.

Source: Nature Reviews Endocrinology - April 17, 2024 Category: Endocrinology Authors: Saleem Ansari Bernard Khoo Tricia Tan Source Type: research